Research site

Düsseldorf 40489

11 studies enrolling now · 55 studies all time

What they study most

AL Amyloidosis, Acute Ischemic Stroke, Advanced Breast Cancer, Advanced ER-Positive HER2-Negative Breast Cancer, Advanced Ovarian Cancer, B-cell Acute Lymphoblastic Leukemia (B-ALL), Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Cancer, Early Breast Cancer, Cardiovascular Disease, Chronic Kidney Disease

Studies at this site

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer — Recruiting now
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer — Recruiting now
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation — Recruiting now
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) — Recruiting now
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) — Recruiting now
• A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients — Recruiting now
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations — Recruiting now
• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer — Recruiting now
• A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — Recruiting now
• AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia — Recruiting now
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension — Completed
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer — Running, not enrolling
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Running, not enrolling
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC — Running, not enrolling
• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) — Running, not enrolling
• Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis — Running, not enrolling
• A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer — Running, not enrolling
• Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin — Running, not enrolling
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis — Stopped early
• Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) — Stopped early
• Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer — Completed
• Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis — Stopped early
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) — Completed
• Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment — Completed
• Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim — Completed
• An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A — Completed
• N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis — Completed
• A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease — Completed
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) — Completed
• Osteonecrosis of the Jaw (ONJ) Case Registry — Completed
• Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke — Completed
• Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma — Completed
• AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) — Stopped early
• Atacicept in Multiple Sclerosis Extension Study, Phase II — Stopped early
• TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer — Stopped early
• Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma — Completed
• Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke — Completed
• A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) — Stopped early
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis — Completed